Autoimmune Diseases  >>  BI 655064  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 655064 / AbbVie, Boehringer Ingelheim
NCT01751776 / 2012-004090-16: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Checkmark ACR-ARHP 2016
Oct 2016 - Oct 2016: ACR-ARHP 2016
Completed
1
107
Europe, RoW
Placebo matching BI 655064, BI 655064
Boehringer Ingelheim
Arthritis, Rheumatoid, Healthy
03/15
04/15
NCT02009761: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Terminated
1
6
US
BI 655064
Boehringer Ingelheim
Purpura, Thrombocytopenic, Idiopathic
04/16
04/16

Download Options